New Two-Step attack on aggressive lymphoma shows promise in early trial
NCT ID NCT05600686
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 2 trial is testing whether a targeted antibody-drug combination (loncastuximab tesirine plus rituximab) followed by standard chemotherapy can improve outcomes for people with high-risk diffuse large B-cell lymphoma. The study enrolls 24 adults with untreated double-expressor or double/triple-hit lymphoma. The approach aims to deliver a potent first strike against cancer cells before completing treatment with chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- loncastuximab tesirine and rituximab followed by chemotherapy (doxorubicin, etoposide, vincristine, cyclophosphamide, prednisone)
- What this could lead to
- If successful, this combination could improve complete response rates and long-term control for people with aggressive, high-risk lymphoma.
- What could go wrong
- This is a small, early-phase trial (24 participants) with no control group, so results may not apply broadly. Chemotherapy side effects can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
UC San Diego Moores Cancer Center
RECRUITINGSan Diego, California, 92037, United States
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?